Low-grade and anaplastic oligodendroglioma

Martin J. Van Den Bent, Jacolien E C Bromberg, Jan Craig Buckner

Research output: Chapter in Book/Report/Conference proceedingConference contribution

5 Citations (Scopus)

Abstract

Anaplastic oligodendrogliomas have long attracted interest because of their sensitivity to chemotherapy, in particular in the subset of 1p/19q co-deleted tumors. Recent molecular studies have shown that all 1p/19q co-deleted tumors have IDH mutations and most of them also have TERT mutations. Because of the presence of similar typical genetic alterations in astrocytoma and glioblastoma, the current trend is to diagnose these tumors on the basis of their molecular profile. Further long-term follow-up analysis of both EORTC and RTOG randomized studies on (neo)adjuvant procarbazine, lomustine, vincristine (PCV) chemotherapy have shown that adjuvant chemotherapy indeed improves outcome, and this is now standard of care. It is also equally clear that benefit to PCV chemotherapy is not limited to the 1p/19q co-deleted cases; potential other predictive factors are IDH mutations and MGMT promoter methylation. Moreover, a recent RTOG study on low-grade glioma also noted an improved outcome after adjuvant PCV chemotherapy, thus making (PCV) chemotherapy now standard of care for all 1p/19q co-deleted tumors regardless of grade. It remains unclear whether temozolomide provides the same survival benefit, as no data from well-designed clinical trials on adjuvant temozolomide in this tumor type are available. Another question that remains is whether one can safely leave out radiotherapy as part of initial treatment to avoid cognitive side-effects of radiotherapy. The current data suggest that delaying radiotherapy and treatment with chemotherapy only may be detrimental for overall survival.

Original languageEnglish (US)
Title of host publicationGliomas, 2016
PublisherElsevier
Pages361-380
Number of pages20
Volume134
ISBN (Print)9780128029978
DOIs
StatePublished - 2016

Publication series

NameHandbook of Clinical Neurology
Volume134
ISSN (Print)00729752
ISSN (Electronic)22124152

Fingerprint

Oligodendroglioma
Lomustine
Procarbazine
temozolomide
Vincristine
Drug Therapy
Radiotherapy
Neoplasms
Standard of Care
Mutation
Astrocytoma
Adjuvant Chemotherapy
Glioblastoma
Glioma
Methylation
Clinical Trials
Therapeutics

Keywords

  • 19q
  • 1p
  • Anaplastic
  • IDH
  • Oligoastrocytoma
  • Oligodendroglioma
  • PCV
  • Temozolomide
  • TERT

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Van Den Bent, M. J., Bromberg, J. E. C., & Buckner, J. C. (2016). Low-grade and anaplastic oligodendroglioma. In Gliomas, 2016 (Vol. 134, pp. 361-380). (Handbook of Clinical Neurology; Vol. 134). Elsevier. https://doi.org/10.1016/B978-0-12-802997-8.00022-0

Low-grade and anaplastic oligodendroglioma. / Van Den Bent, Martin J.; Bromberg, Jacolien E C; Buckner, Jan Craig.

Gliomas, 2016. Vol. 134 Elsevier, 2016. p. 361-380 (Handbook of Clinical Neurology; Vol. 134).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Van Den Bent, MJ, Bromberg, JEC & Buckner, JC 2016, Low-grade and anaplastic oligodendroglioma. in Gliomas, 2016. vol. 134, Handbook of Clinical Neurology, vol. 134, Elsevier, pp. 361-380. https://doi.org/10.1016/B978-0-12-802997-8.00022-0
Van Den Bent MJ, Bromberg JEC, Buckner JC. Low-grade and anaplastic oligodendroglioma. In Gliomas, 2016. Vol. 134. Elsevier. 2016. p. 361-380. (Handbook of Clinical Neurology). https://doi.org/10.1016/B978-0-12-802997-8.00022-0
Van Den Bent, Martin J. ; Bromberg, Jacolien E C ; Buckner, Jan Craig. / Low-grade and anaplastic oligodendroglioma. Gliomas, 2016. Vol. 134 Elsevier, 2016. pp. 361-380 (Handbook of Clinical Neurology).
@inproceedings{9bd1389adc6a49aba0348c60e04addba,
title = "Low-grade and anaplastic oligodendroglioma",
abstract = "Anaplastic oligodendrogliomas have long attracted interest because of their sensitivity to chemotherapy, in particular in the subset of 1p/19q co-deleted tumors. Recent molecular studies have shown that all 1p/19q co-deleted tumors have IDH mutations and most of them also have TERT mutations. Because of the presence of similar typical genetic alterations in astrocytoma and glioblastoma, the current trend is to diagnose these tumors on the basis of their molecular profile. Further long-term follow-up analysis of both EORTC and RTOG randomized studies on (neo)adjuvant procarbazine, lomustine, vincristine (PCV) chemotherapy have shown that adjuvant chemotherapy indeed improves outcome, and this is now standard of care. It is also equally clear that benefit to PCV chemotherapy is not limited to the 1p/19q co-deleted cases; potential other predictive factors are IDH mutations and MGMT promoter methylation. Moreover, a recent RTOG study on low-grade glioma also noted an improved outcome after adjuvant PCV chemotherapy, thus making (PCV) chemotherapy now standard of care for all 1p/19q co-deleted tumors regardless of grade. It remains unclear whether temozolomide provides the same survival benefit, as no data from well-designed clinical trials on adjuvant temozolomide in this tumor type are available. Another question that remains is whether one can safely leave out radiotherapy as part of initial treatment to avoid cognitive side-effects of radiotherapy. The current data suggest that delaying radiotherapy and treatment with chemotherapy only may be detrimental for overall survival.",
keywords = "19q, 1p, Anaplastic, IDH, Oligoastrocytoma, Oligodendroglioma, PCV, Temozolomide, TERT",
author = "{Van Den Bent}, {Martin J.} and Bromberg, {Jacolien E C} and Buckner, {Jan Craig}",
year = "2016",
doi = "10.1016/B978-0-12-802997-8.00022-0",
language = "English (US)",
isbn = "9780128029978",
volume = "134",
series = "Handbook of Clinical Neurology",
publisher = "Elsevier",
pages = "361--380",
booktitle = "Gliomas, 2016",

}

TY - GEN

T1 - Low-grade and anaplastic oligodendroglioma

AU - Van Den Bent, Martin J.

AU - Bromberg, Jacolien E C

AU - Buckner, Jan Craig

PY - 2016

Y1 - 2016

N2 - Anaplastic oligodendrogliomas have long attracted interest because of their sensitivity to chemotherapy, in particular in the subset of 1p/19q co-deleted tumors. Recent molecular studies have shown that all 1p/19q co-deleted tumors have IDH mutations and most of them also have TERT mutations. Because of the presence of similar typical genetic alterations in astrocytoma and glioblastoma, the current trend is to diagnose these tumors on the basis of their molecular profile. Further long-term follow-up analysis of both EORTC and RTOG randomized studies on (neo)adjuvant procarbazine, lomustine, vincristine (PCV) chemotherapy have shown that adjuvant chemotherapy indeed improves outcome, and this is now standard of care. It is also equally clear that benefit to PCV chemotherapy is not limited to the 1p/19q co-deleted cases; potential other predictive factors are IDH mutations and MGMT promoter methylation. Moreover, a recent RTOG study on low-grade glioma also noted an improved outcome after adjuvant PCV chemotherapy, thus making (PCV) chemotherapy now standard of care for all 1p/19q co-deleted tumors regardless of grade. It remains unclear whether temozolomide provides the same survival benefit, as no data from well-designed clinical trials on adjuvant temozolomide in this tumor type are available. Another question that remains is whether one can safely leave out radiotherapy as part of initial treatment to avoid cognitive side-effects of radiotherapy. The current data suggest that delaying radiotherapy and treatment with chemotherapy only may be detrimental for overall survival.

AB - Anaplastic oligodendrogliomas have long attracted interest because of their sensitivity to chemotherapy, in particular in the subset of 1p/19q co-deleted tumors. Recent molecular studies have shown that all 1p/19q co-deleted tumors have IDH mutations and most of them also have TERT mutations. Because of the presence of similar typical genetic alterations in astrocytoma and glioblastoma, the current trend is to diagnose these tumors on the basis of their molecular profile. Further long-term follow-up analysis of both EORTC and RTOG randomized studies on (neo)adjuvant procarbazine, lomustine, vincristine (PCV) chemotherapy have shown that adjuvant chemotherapy indeed improves outcome, and this is now standard of care. It is also equally clear that benefit to PCV chemotherapy is not limited to the 1p/19q co-deleted cases; potential other predictive factors are IDH mutations and MGMT promoter methylation. Moreover, a recent RTOG study on low-grade glioma also noted an improved outcome after adjuvant PCV chemotherapy, thus making (PCV) chemotherapy now standard of care for all 1p/19q co-deleted tumors regardless of grade. It remains unclear whether temozolomide provides the same survival benefit, as no data from well-designed clinical trials on adjuvant temozolomide in this tumor type are available. Another question that remains is whether one can safely leave out radiotherapy as part of initial treatment to avoid cognitive side-effects of radiotherapy. The current data suggest that delaying radiotherapy and treatment with chemotherapy only may be detrimental for overall survival.

KW - 19q

KW - 1p

KW - Anaplastic

KW - IDH

KW - Oligoastrocytoma

KW - Oligodendroglioma

KW - PCV

KW - Temozolomide

KW - TERT

UR - http://www.scopus.com/inward/record.url?scp=84976394937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976394937&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-802997-8.00022-0

DO - 10.1016/B978-0-12-802997-8.00022-0

M3 - Conference contribution

C2 - 26948366

AN - SCOPUS:84976394937

SN - 9780128029978

VL - 134

T3 - Handbook of Clinical Neurology

SP - 361

EP - 380

BT - Gliomas, 2016

PB - Elsevier

ER -